A resilient medtech industry navigating the fallout from President Donald Trump’s trade wars is taking proactive steps to ...

Study investigators cautioned against routine use of the device in complex percutaneous coronary interventions and to treat ...

The company disclosed that it expects a material impact on first-quarter financial results. However, it does not expect an ...

The appointment gives a former Abbott leader oversight of efforts to bring a pulsed field ablation device to market.

The FDA said it intends to hire “substantial numbers” of medical device review staff as part of the agreement for the next ...

View Point sells tumor tissue localization devices that could complement Merit’s existing presence in the sector.

With approval to study the transcatheter replacement device in patients with severe tricuspid regurgitation, VDyne is ...

The center plans to pick nine devices to help support patients and caregivers after a hospital stay.

The company is seeking clearance in additional gynecological indications to support outpatient use of its surgical robot.

The company appointed Almeida as chief executive in conjunction with the completion of an $18.3 billion go-private deal.

The deal positions Boston Scientific to compete with Medtronic for a market that analysts believe is highly under-penetrated.

The Varipulse Pro pulsed field ablation platform, which has received a CE mark, will be a focus at the upcoming European ...